Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Project Oncology®
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Project Oncology®
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Angel Qin, MD
- Angel Qin, MD
Investigating Unanswered Questions in ALK+ mNSCLC Care
Investigating Unanswered Questions in ALK+ mNSCLC Care
Project Oncology®
Investigating Unanswered Questions in ALK+ mNSCLC Care
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Patterns of Progression and Resistance in ALK+ mNSCLC
Patterns of Progression and Resistance in ALK+ mNSCLC
Project Oncology®
Patterns of Progression and Resistance in ALK+ mNSCLC
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Project Oncology®
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
Project Oncology®
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Oncology and Hematology
Updated Overall Survival From Stage 1 of PRESERVE-003: Gotistobart vs Docetaxel in Metastatic Squamous NSCLC After Anti-PD-(L)1 Progression
Byoung Chul Cho, MD, PhD
- Byoung Chul Cho, MD, PhD
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP

Medical News

Medical News
Roginolisib Trial Shows PI3Kδ Target Engagement in Uveal Melanoma
10/13/2026
Read more
Medical News
CT Body Composition Radiomics Improves NSCLC Survival Prediction
10/12/2026
Read more
Medical News
KRAS/TP53 Co-Mutation Linked to Better ICI Outcomes in LUAD
10/12/2026
Read more
Medical News
Checkpoint Inhibitor Rheumatic Toxicity in ERIN Registry
10/12/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits

Clinical Practice

Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Project Oncology®
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Steve Jackson, PharmD; Paolo F. Caimi, MD
- Steve Jackson, PharmD
- Paolo F. Caimi, MD
- Narendranath Epperla, MD, MS
Guiding mNSCLC Treatment After ALK-TKI Progression
Guiding mNSCLC Treatment After ALK-TKI Progression
Project Oncology®
Guiding mNSCLC Treatment After ALK-TKI Progression
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Advancing Metastatic Breast Cancer Research Through Philanthropy
Advancing Metastatic Breast Cancer Research Through Philanthropy
On the Frontlines of Metastatic Breast Cancer
Advancing Metastatic Breast Cancer Research Through Philanthropy
Steve Jackson, PharmD; Ted Giovanis, FHFMA, MBA
- Steve Jackson, PharmD
- Ted Giovanis, FHFMA, MBA
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Alexandria May, PharmD, BCPS; Donald McDonnell, PhD
- Alexandria May, PharmD, BCPS
- Donald McDonnell, PhD
- Neil M. Iyengar, MD

Programs

Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Clinician's Roundtable
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Brian P. McDonough, MD, FAAFP; David A. Johnson, MD, FACG, FACP
- Brian P. McDonough, MD, FAAFP
- David A. Johnson, MD, FACG, FACP
How ALK Vaccines Could Prolong TKI Response in mNSCLC
How ALK Vaccines Could Prolong TKI Response in mNSCLC
Project Oncology®
How ALK Vaccines Could Prolong TKI Response in mNSCLC
Angel Qin, MD
- Angel Qin, MD
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Project Oncology®
Why Molecular Testing Matters in Non-Small Cell Lung Cancer
Geoffrey Oxnard, MD
- Geoffrey Oxnard, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
- Laura Alder, MD